Richard N. Greenberg, M.D.
Professor of Medicine and Acting Chief, Division of
   Infectious Diseases
The Belinda Mason Carden and Paul Mason Professor
   of HIV/AIDS Research and Education, 2001-2006

Medical School
Tufts University School of Medicine

Residency
Indiana University Medical Center, Indianapolis, IN
Louisiana State University, New Orleans

Fellowships
Infectious Diseases, Louisiana State University Medical Center
NIH Training, University of Virginia Medical Center

Board Certifications
American Board of Internal Medicine
American Board of Internal Medicine, Subspecialty of Infectious Diseases

Special Training
Special Consultant for Smallpox Eradication Program, WHO,
    Bihar State, India, 1974-5
EIS Officer assigned to New Orleans, CDC, 1974-6

Clinical Interests
•  HIV/AIDS
•  Treatment for fungal infections
•  Treatment and prevention for C.difficile disease
•  Treatment for infections in febrile neutropenic patients
•  Vaccine development and trials: Hep A & B ,VZV, vaccinia, bioterrorism,     pneumococcal, HIV
•  Treatment and prevention of viral diseases (e.g., West Nile)

Research Interests
•  Physiology of E. coli heat stable enterotoxin and its family of
   endogenous human hormones including guanylin and
   uroguanylin.
•  Lipid physiology and toxicity of HIV protease inhibitor
•  Vaccine trials including vaccines that protect against HIV, hepatitis
   viruses, pneumococcal disease, and bioterrorism (e.g., smallpox,
   anthrax).
•  Early phase trials of antimicrobials or other therapies directed against
    HIV, community-acquired pneumonia, Clostridium difficile, and
    fungal infections.

Current Grant Activity

2002/2003 Publications
Carrithers SL, BA Jackson, WY Cai, RN Greenberg, CE Ott. Regulation of intestinal guanylin and uroguanylin mRNA expression by dietary salt intake. Regulatory Peptides 2002 Jul 15;107(1-3):87-95.

Mayhew CN, LJ Mampuru, D Chendil, MM Ahmed, JD Phillips, RN Greenberg, HL Elford and VS Gallicchio. Suppression of retrovirus-induced immunodeficiency disease (murine AIDS) by trimidox and didox: novel ribonucleotide reductase inhibitors with less bone marrow toxicity than hydroxyurea. Antiviral Res. 2002;56:167-81.

Walsh TJ, P Pappas, D Winston, HM Lazarus, F Petersen, J Raffalli, S Yanovich, P Stiff, RN Greenberg, G Donowitz, and J Lee, for the NIAID Mycoses Study Group. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. New Engl J Med 346:225-234, 2002.

Greenberg RN, PJ Cagnoni, JR Wingard, MM Prendergast, KB Tong. Factors associated with increased hospital costs in patients treated with lipid-based amphotericin B for empirical therapy. Journal of Medical Economics 5:109-118, 2002.

Martin C, S Roberts, and RN Greenberg. Voriconazole treatment of disseminated paecilomyces infection in a patient with acquired immunodeficiency syndrome. Clin Infect Dis. 2002 Oct 1;35(7):e78.

Richard Greenberg--infectious disease specialist at the University of Kentucky Chandler Medical Center interviewed by Pam Das. Lancet Infect Dis. 2003 Jan:3(1):52-5.

MS Santos-Neto, SL Carrithers, A Carvalho, HAS Monteiro, RN Greenberg, LR Forte, and MC Fonteles. Guanylin and its lysine-containing analogue in the isolated perfused rat kidney: interaction with chymotrypsin inhibitor. Pharmacology and Toxicology 2003,92:114-120.

Dressman J, J Kincer, SV Matveev, L Guo, RN Greenberg, T Guerin, d Meade, X-A Li, W Zhu, A Uittenbogaard, ME Wilson, and E Smart. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. Journal of Clinical Investigation 2003,111:389-397.

Greenberg RN, J Feinberg, J Goodrich, RS Pilson, and P Siemon-Hryczyk. Long-term efficacy and safety of twice-daily saquinavir soft gel capsule (SGC), with or without nelfinavir, and three-times-daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up. Antiviral therapy 2003,8:37-42.

Perfect JR, KA Marr, TJ Walsh, RN Greenberg, B DuPont, J de-la-Torre-Cisneros, G Just-Nubling, HT Schlamm, I Lutsar, A Espinel-Ingroff, E Johnson. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003, 6(9):1122-31.

2002/2003 Abstracts
Carrithers SL, C Pager, Rshah, R Greenberg. Uroguanylin activates the extracellular-regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK), and p38 mitogen activated protein kinase in colon carcinoma cells via c GMP. Experimental Biology 2002, April 2002, New Orleans, La.

Ott CE, BA Jackson, RN Greenberg, SL Carrithers. Effect of E.coli heat-stable enterotoxin STa, a mimic of the endogenous guanylin peptide family, on renal function in rats on a low salt diet. Experimental Biology 2002, April 2002, New Orleans, La.

Avison MJ, A Nath, RG Avison, R Greenberg, FA Schmitt, JR Berger. MR predictors of HIV dementia. 4th International Symposium of NeuroVirology and 10th Conference on Neuroscience of HIV Infection, Dusseldorf Germany, June 2002.

Avison MJ, A Nath, RG Avison, R Bales, R Greenberg, F Schmitt, JR Berger. 1H-MRS, MRI, and CSF predictors of HIV dementia: Preliminary results from ongoing longitudinal studies. Amer Acad Neurol. 54th Annual Meeting, Denver CO, April 2002.

Greenberg RN, CE Ott, BA Jackson, SL Carrithers. Effect of Uroguanylin and E coli heat-stable enterotoxin STa onrenal function in rats on a low and normal salt diet. . Experimental Biology 2003, April 2003, San Diego CA.

Hopkins RJ, RN Greenberg, EA Plummer, L Hague, D Clanton, V Johnson, D Fine, M Langford. Take rate and safety of a new cell-cultured smallpox vaccine. ASM Biodefense Research Meeting. Baltimore MD, March 2003.

Avison MJ, A Nath, RG Avison, R Bales, R Greenberg, F Schmitt, JR Berger. Microglial activation and BBB compromise in HIV-infected patients. 55th Annual Meeting of the Amer. Acad. Neurol. Oahu Hawaii, April 2003.

Greenberg RN, BA Plummer, SA Roberts, MA Caldwell, DL Hargis, RJ Hopkins. Expected but unusual rashes in adults after first Vaccinia vaccination. 6th Annual Conference on Vaccine Research (NFID). Arlington MD, May 2003.

RJ Hopkins, R N Greenberg E A Plummer, L Hague, D Clanton, V Johnson, D Fine, M Langford. Clinical Results of New Cell-Cultured Smallpox Vaccine Evaluation: An Update. 43rd annual ICAAC, Chicago IL, September 14-17, 2003.

R N Greenberg, G Anstead, R Herbrecht, A Langston, K Marr, K Mullane, I Raad, G Schiller, M Schuster, J Van Burik , J R Wingard, R Hare, G Corcoran. Posaconazole (POS) Experience in the Treatment of Zygomycosis. 43rd annual ICAAC, Chicago IL, September 14-17, 2003.

Kennedy, JS, RJ Hopkins, DJ Clanton, RN Greenberg, J Cruz, and FA Ennis. Human T-Cell Immune Responses of a New Cell-Cultured Derived
Smallpox Vaccine: Phase 1 Comparative Trial to Dryvax(r). Proceedings of the 41st Annual Meeting of Infectious Diseases Society of America, San Diego, October 9-12, 2003.